Panel: A Look at Biopharma M&A and Shifting Deal Dynamics
In A Look at Biopharma M&A and Shifting Deal Dynamics, industry leaders from Merck, Avenzo Therapeutics and Astellas Pharma will examine the intricacies of biopharma transactions and a future of regulatory challenges and changed market forces.
Join us for a panel discussion where we navigate the landscape of biopharma M&A. In this session, experts will explore the ever-evolving deal dynamics within the industry, all while addressing the question: Will the FTC's increasing scrutiny put a brake on deals in 2024? Prepare to examine the intricacies of biopharma transactions and gain valuable insights into their future in the face of regulatory challenges and market forces.
Moderators
Max Bayer
Staff Writer, Fierce Biotech
Max Bayer is a staff writer for Fierce Biotech. He joined after more than three years at CBS News, two of which were spent covering the twists and turns of the COVID-19 pandemic, from infection trends to CDC guidelines.
Speakers
Elizabeth Naldi Jacob
Head of Oncology BD & Headquarters Transactions, Merck
Elizabeth Naldi-Jacob is Vice President and responsible for all BD&L HQ transactions and corporate development. Her deal remit includes all therapeutic areas and different deal types such as license, partnership, M&A, out-license, clinical collaboration, among others.
Athena Countouriotis, MD
CEO and Co-Founder, Avenzo Therapeutics
Athena Countouriotis, M.D., is co-founder, President, Chief Executive Officer and Chairperson of Avenzo Therapeutics. She most recently led Turning Point Therapeutics as President and Chief Executive Officer through its IPO in 2019 to its eventual acquisition by Bristol Myers Squibb.
Issei Tsukamoto, Ph.D.
Senior Vice President, Head of Business Development, Astellas Pharma Inc.
Issei Tsukamoto is senior vice president and global Head of Business Development (BD) at Astellas, based out of Tokyo, Japan. He has responsibility for leading the company’s full range of dealmaking and partnering activities, from venture investments and R&D collaborations to late-stage licensing and M&As, building win-win partnerships.
For more, please find the original story source here.
